Filing excerpt
On February 24, 2026, AbbVie Inc. (“AbbVie”) entered into an underwriting agreement (the “Underwriting Agreement”)...
sec.gov/Archives/edgar/data/1551152/000110465926020643/tm266774d4_8k.htmRead the full source
AbbVie8-K: Material contract
AbbVie raises ~$7.95B in capital through senior notes offering to repay debt and fund corporate purposes.
What happened
AbbVie secured nearly $8 billion in net proceeds from a major debt offering via an underwriting agreement.
Source
Other signals in this filing (2)
- Debt refinancingAbbVie raises $7.95B in net proceeds from senior notes offering to refinance existing debt.Debt refinancing
- Automation investmentAbbVie raises ~$7.95B in net proceeds via debt offering for refinancing and corporate purposes.Automation investment
Extracted by Autobound
From the Signal API record- Signal
- 8-K: Material contract
What this signalsFilings often name leadership changes, deals and spending plans.
- Form
- 8-K
- Dollar figure
- $8B (net proceeds from senior notes offering)
- Filed
- Feb 26, 2026
More from AbbVie
- PartnershipAbbVie Teams Up With Valkai to Use AI in Clinical DevelopmentPartnership
- IntegrationValkai partners with AbbVie to apply advanced AI in targeted areas of clinical developmentIntegration
- PatentsAbbVie Inc.'s patent output is steady: 3 grants in the past year, 0 in the past 30 days.Patents
- LaunchU.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's DiseaseLaunch
- RedditCommenters describe AbbVie as a challenging employer for Clinical Research Associates, citing a "ridiculous" work-life balance and a "toxic" environment with frequent, disruptive rollouts of new...Reddit
- InvestmentDrug developer ADARx seeks $1.74 billion valuation in US IPOInvestment
More 8-K signals at other companies
- SEC 8-K4D Molecular Therapeutics, Inc.4D Molecular Therapeutics initiates Phase 3 trial directly challenging competitor drug aflibercept.SEC 8-K
- SEC 8-KAdeia Inc.Adeia Inc. appoints new CEO Dipti Vachani, effective October 12, 2026, replacing outgoing CEO Paul E. Davis.SEC 8-K
- SEC 8-KAdicet Bio, Inc.Adicet Bio launching pivotal clinical trial in Q4 2026 after positive Phase 1 data for Prula-cel.SEC 8-K
The full record
From the Signal API recordDetails
- CIK
- 1551152
- Accession number
- 0001104659-26-020643
- Timeframe
- Immediate
- Filing year
- 2026
- Why it matters
- Vendor relationship signal
- Signal category
- Strategic
Topics and mentions
Vendors
- J.P. Morgan Securities LLC
- BofA Securities
- Inc.
- Morgan Stanley & Co. LLC
- Wells Fargo Securities
- LLC
Vendors named
- J.P. Morgan Securities LLC
- BofA Securities, Inc.
- Morgan Stanley & Co. LLC
- Wells Fargo Securities, LLC
Extraction
- Confidence
- High
- Relevance
- 90%
- Sentiment
- Neutral
- Detected
- Mar 3, 2026
- signal_type
sec-8k- signal_subtype
materialContract
Use this data
Get every 8-K signal for AbbVie and the companies you sell to, in the tools you already use.
Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AbbVie this week?”
Send it to your own tools
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits
The API returns more than this page shows
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the API
Signal
signal_nameValue in the APIassociationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONHide the full JSONThe record on this page and the API request
GET /v1/signals/a4c89a1b-4cc5-45d6-bc60-4ef552564b11 returns this record as JSON. POST /v1/companies/enrich returns every signal for abbvie.com.
{
"signal_id": "a4c89a1b-4cc5-45d6-bc60-4ef552564b11",
"signal_type": "sec-8k",
"signal_subtype": "materialContract",
"detected_at": "2026-03-03T08:25:03.86+00:00",
"company": {
"name": "AbbVie",
"domain": "abbvie.com"
},
"data": {
"detail": "AbbVie secured nearly $8 billion in net proceeds from a major debt offering via an underwriting agreement. This massive capital influx, earmarked for repaying a $2B loan and for 'general corporate purposes,' signals significant available budget for strategic investments, technology upgrades, or other large-scale projects.",
"metrics": {
"timeframe": "immediate",
"dollar_context": "net proceeds from senior notes offering",
"dollar_millions": 7950
},
"summary": "AbbVie raises ~$7.95B in capital through senior notes offering to repay debt and fund corporate purposes.",
"excerpts": "On February 24, 2026, AbbVie Inc. (“AbbVie”) entered into an underwriting agreement (the “Underwriting Agreement”)...",
"relevance": 0.9,
"sentiment": "neutral",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1551152/000110465926020643/tm266774d4_8k.htm",
"filing_date": "2026-02-26",
"filing_year": 2026,
"sales_relevance": "Vendor relationship signal",
"signal_category": "strategic",
"vendors_mentioned": [
"J.P. Morgan Securities LLC",
"BofA Securities, Inc.",
"Morgan Stanley & Co. LLC",
"Wells Fargo Securities, LLC"
]
}
}
curl https://signals.autobound.ai/v1/signals/a4c89a1b-4cc5-45d6-bc60-4ef552564b11 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbvie.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.